Secondary hyperparathyroidism - Open Access .click

Results 131 to 140 of about 47,738 (289)

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract Although poly(adenosine diphosphate‐ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first‐line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA‐mutated/homologous recombination‐deficient (HRD) patients, is lacking.
Lingying Wu +56 more
wiley +1 more source

New therapies: calcimimetics, phosphate binders and vitamin D receptor activators [PDF]

, 2010
At present, new compounds are available to treat secondary hyperparathyroidism, namely calcimimetics, novel phosphorus binders and also novel vitamin D receptor activactors.
Cannata, J.B. (Jorge) +5 more
core

Efficacy of Cinacalcet for the Treatment of Secondary Hyperparathyroidism in CKD Patients on Peritoneal or Hemo Dialysis: The Middle-East Experience

, 2012
Abdullah Al‐Hwiesh, Ahmed Alsaloom, Krishan Lal Gupta +2 more
openalex +1 more source

GRP-056 Effect of Pharmaceutical Follow-Up in Patients with Secondary Hyperparathyroidism Treated with Cinacalcet [PDF]

, 2013
FPA Fernández Pérez Ana +4 more
openalex +1 more source

The effect of continuous infusion of human parathyroid hormone on bone architecture in female mice [PDF]

, 2009
Thesis (S.B.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering, 2009."June 2009." Cataloged from PDF version of thesis.Includes bibliographical references (p.
Eisenberg, Rahel E. (Rahel Esther)
core

The High Calcium, High Phosphorus Rescue Diet Is Not Suitable to Prevent Secondary Hyperparathyroidism in Vitamin D Receptor Deficient Mice [PDF]